Mr. Paul Romness, with over 25 years in biopharma, has led product launches for major companies like Johnson & Johnson and Amgen, focusing on unmet medical needs. He holds degrees in finance and health policy.
Our technology is currently being tested in human clinical trials. Click below to learn more about them.
Mr. Paul Romness, with over 25 years in biopharma, has led product launches for major companies like Johnson & Johnson and Amgen, focusing on unmet medical needs. He holds degrees in finance and health policy.
Dr. Robert Petit is a seasoned biopharma executive and medical scientist who has held C-Suite roles across biotech, oncology, immunology, and infectious disease. Robert excels in corporate strategy, clinical and scientific development, and regulatory affairs.
Gerald is a healthcare executive who's spent 15+ years in the C-Suite, leading growth in therapeutics, diagnostics, and natural products. To date, he has raised over $70M in capital and holds a BS from Stanford.
Dr. Jutta Wanner, former CSO at BlinkBio, brings her Advanced ADC technology and expertise in oncology, inflammation, and virology. She previously co-led discovery chemistry at Roche and holds a PhD from the University of Kansas.
OS Therapies is at the frontlines of propelling cancer treatment technology and working to revolutionize cancer treatment.
Mr. Paul Romness, with over 25 years in biopharma, has led product launches for major companies like Johnson & Johnson and Amgen, focusing on unmet medical needs. He holds degrees in finance and health policy.
Colin Goddard, former CEO of BlinkBio and OSI Pharmaceuticals, led Tarceva's development and OSI’s $4B acquisition by Astellas. He chairs Mission Therapeutics, serves on Endocyte's board, and holds a PhD in cancer chemotherapy.
John Ciccio, COO of Technology & Data Solutions at Syneos Health and former CEO of Adheris Health, specializes in patient management solutions using behavioral models and data analytics. He holds an undergraduate degree from Harvard University.
Dr. Theodore Search, Pharm.D., is GM-CEO of Real-World Data Intelligence at Nestella and founder of Skipta, a network for verified healthcare professionals to collaborate on patient cases. He holds a Pharm.D. from the University of Pittsburgh.
Joacim Borg is the Chief Marketing Officer at Index Investment Group, leading North American marketing and branding for development projects and investments. He currently holds a BS in Managerial Economics from Bentley University.
Olivia Egge was diagnosed with Osteosarcoma in 2017. Since then, she inspires the search for new OS treatments by sharing valuable patient insights. Olivia is currently a 4th-year student at the University of Virginia.
Ms. McKean Dieser, VP and Head of Legal Patient Evidence at UCB, Inc., brings 21+ years of pharmaceutical legal, regulatory, and corporate governance expertise, complemented by her legal, public administration, and English literature education.
Mr. Jarry, Co-founder and CEO of Libera Bio S.L., offers 40+ years of biopharma leadership across oncology, neuroimmunology, cell therapy, and digital therapeutics.
